FANCD2 and pancreatic adenocarcinoma: (42) conducted a study on the ferroptosis regulator and its association with the immune microenvironment and programmed cell death ligand 1 (PD-L1) in pancreatic adenocarcinoma, and it was found that FANCD2 could be effective for prognostic recognition, immune efficacy evaluation, and mRNA vaccine for patients with pancreatic adenocarcinoma.